c-MET expression potentially contributes to the poor prognosis of rhabdomyosarcoma

Juan Du; Yuanyuan Wang; Lian Meng; Yang Liu; Yuwen Pang; Wenwen Cui; Liang Zhang; Zhenzhen Li; Qianqian Liu; Hao Shang; Chunxia Liu; Feng Li

c-MET expression potentially contributes to the poor prognosis of rhabdomyosarcoma

Int J Clin Exp Pathol. 2018 Aug 1;11(8):4083-4092. eCollection 2018.

Authors

Juan Du¹, Yuanyuan Wang¹, Lian Meng¹, Yang Liu¹, Yuwen Pang¹, Wenwen Cui¹, Liang Zhang¹, Zhenzhen Li¹, Qianqian Liu¹, Hao Shang¹, Chunxia Liu¹, Feng Li^{1

2}

Affiliations

¹ Department of Pathology, School of Medicine, Shihezi University Shihezi, Xinjiang, China.
² Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University Beijing, China.

PMID: 31949799
PMCID: PMC6962817

Abstract

Rhabdomyosarcoma (RMS) is one of the most common soft-tissue sarcomas with a poor prognosis. c-MET is a prognostic biomarker associated with growth, proliferation, invasion, and metastasis in various carcinomas. In this study, we aim to investigate the expression of c-MET in RMS and its effect on the prognosis of patients with rhabdomyosarcoma. We performed immunohistochemistry and a quantitative real-time polymerase chain reaction (qRT-PCR) to determine the expression levels of c-MET proteins and mRNAs. Results indicated that the c-MET protein and mRNA expression levels in the RMS samples were significantly higher than those in normal controls (P<0.01 and P=0.0492). However, the correlation between c-MET expression and any other clinicopathological parameter and survival was not significant (P=0.837). Nevertheless, c-MET expression had a significant influence on the overall survival rates of patients with ERMS (χ²=9.673, P=0.002) and fusion gene-negative patients (χ²=5.400, P=0.020). These findings suggest that c-MET may serve as a promising biomarker capable of predicting poor prognosis in patients with RMS.

Keywords: Rhabdomyosarcoma; c-MET; immunohistochemistry; prognosis; qRT-PCR.